Used in pharmaceutical research as a key intermediate in the synthesis of kinase inhibitors, particularly for targeting cancer-related enzymes such as BRAF or EGFR mutants. Its structure supports high selectivity and binding affinity in small-molecule drug candidates. Commonly employed in preclinical studies to develop treatments for solid tumors, especially melanoma and non-small cell lung cancer. Also utilized in structure-activity relationship (SAR) studies to optimize potency, metabolic stability, and bioavailability of new oncology agents.